ABSTRACT -Toxicity screening of a newly developed oral heparin derivative was carried out in twelve male cynomolgus monkeys (Macaca fascicularis), composed of three treatment and vehicle control groups. A newly orally active heparin derivative, developed by Seoul National University, was given to the treatment group at three doses with low (12.8 mg/kg), medium (89.6 mg/kg) and high (640 mg/kg) doses for 14 days. A treatment group did not show any change in body weights, hematological parmeters (e.g., RBC, WBC, platelet, PDW, MPV, etc.) and serum biochemical parameters (e.g., AST, ALT, BUN, etc.) for 2 weeks compared with those of the vehicle control group. These findings indicated that the oral anticoagulant drug, a newly developed oral heparin derivative, did not have any toxic effect for 2 week in this study. The present study will be valuable in the proper interpretation for non-clinical study using cynomolgus monkeys in the development of a new drug of heparin derivative.
INTRODUCTION
The physiological function of the coagulation system acts to prevent blood loss after injury. However, certain events such as damage to the vessel wall or changes in blood flow can produce changes in the processes of coagulation that result in the pathological event of thrombosis (Hirsh, 2003) . Given the central role of thrombin in the development of a thrombus, many strategies for preventing and treating thromboembolic events have focused on inhibiting thrombin generation or blocking its activity (Aken et al. 2001; Hirsh 2003; Gonze et al., 2000; Strandness, 2001 ). Venous thromboembolism is recognized in approximately 250,000 hospitalized patients annually, and about 100,000 patients die each year due to pulmonary embolism (PE) in the US (Hirsh and Fuster, 1994; Alpert and Dalen 1994) . Without therapy, these patients have a 50% chance of succumbing to recurrent thromboembolism (Hull et al., 1979 (Hull et al., , 1982 .
Heparin is regarded as the most potent anticoagulant that can be used in preventing deep vein thrombosis (DVT) and pulmonary embolism (PE) (Jack et al., 2001; Ginsberg, 1999) . Heparin acts as an anticoagulant by activating antithrombin, which then inhibits thrombin and FXa (Hirsh, 2003) . However, heparin cannot be absorbed in the intestine owing to its large molecular size and hydrophilicity, and can only be given parenterally. To overcome the poor oral bioavailability of heparin, several research groups have attempted various methods for oral heparin delivery, such as liposomes, oil-water emulsions, complexes of heparin with hydrophobic organic bases, enteric coating, and aerosol formulations (Gonze et al., 2000; Welt et al., 2001; Baughman et al., 1998; Jiao et al., 2002) .
Currently, the so called 'gold-standard' treatment consisting of 5-day injection of parenteral heparin followed by 3 months of oral warfarin therapy can successfully prevent 95% of PE patients with proximal DVT (Hyers et al., 1995) . Warfarin, however, has a slow onset, and is subjected to a low therapeutic efficacy and high possibility of drug-drug interactions (Hull et al., 1982) . Therefore, the development of orally active heparin would have tremendous clinical importance as it would become a choice drug to effectively prevent DVT and PE in a long-term chronic treatment. An oral anticoagulant drug, a newly developed oral heparin derivative, was synthesized by College of Pharmacy of Seoul National University (Lee et al., 1998 (Lee et al., , 2001 Kim et al., 2006) .
However, the side effects of heparin have been reported such as osteopenia and heparin-induced thr ombo cytopen ia (H IT) (C in es et a l., 2 007 ; Menajovsky, 2005) . Osteopenia is caused as a result of the binding of heparin to osteoblast (Shauhnessy et al., 1995) , which then release factors that activate osteoclast, whereas HIT results from heparin binding to platelet factor 4 to form an epitope to which the HIT antibody binds (Visentin et al., 1994; Greinacher et al., 1994) . To confirm the possibility, we carried out toxicity screening for 2-week doses of a new orally active heparin derivative in cynomolgus monkeys.
MATERIALS AND METHODS

Animals
Twelve male cynomolgus monkeys, captive-bred at Guangxi Primate Center, China, were used in this study. They were obtained from Hamri Co. Ltd. (Japan) at 3 to 5 years of age, and were quarantined at the non-human primate facility for four weeks. The monkeys were also subjected to various external physical examinations, tuberculin testing, and microbiological testing for salmonella, shigella, and yersinia examination (data not shown). The feces and urine in their cage pans were examined prior to disposal. The waste was disposed of carefully so as to minimize the creation of aerosol. During the quarantine period, their cages were cleaned daily. All animals used in this study were cared for in accordance with the principles outlined in the "Guide for the Care and Use of Laboratory Animals", a NIH publication. Body weights ranged from 3.541 to 5.512 kg. The animal room was maintained at a temperature of 23 ± 3°C, relative humidity of 55 ± 10%, air ventilation of 10 to 20 times/hour and a light intensity of 150 to 300 Lux with a 12-hr light/dark cycle. Throughout the study, the monkeys were housed individually in stainless steel wire cages (450W × 650L × 754H mm), and fed a standard monkey diet (Oriental Yeast Co., Tokyo, Japan). The UV-irradiated and filtered municipal tap water was provided to animals ad libitum.
Preparation of a test article of chemical conjugate of LMWH and DOCA
The chemical conjugate of low molecule weight heparin (LMWH) and deoxycholic acid (DOCA) was synthesized by conjugating the carboxylic group of DOCA with the carboxylic group of LMWH as described in the previous study Lee et al., 1998 Lee et al., , 2001 Lee et al., , 2006 . The test article was synthesized by College of Pharmacy of Seoul National University (Fig. 1) .
General procedure
An acclimatization period of more than 4 weeks will be allowed between receipt of the animals and the start of treatment to accustom the monkeys to the laboratory environment. Each animal was identified by femoral region tattoo and each cage was identified by cage card with the following information. Twelve monkeys were assigned to vehicle control groups and three 
heparin treatment groups with low (12.8 mg/kg), medium (89.6 mg/kg) and high (640 mg/kg) doses. The vehicle control or test articles were administered orally once daily. Animals were dosed at a volume of 1.5 mL/kg. The blood samples were obtained from the cephalic vein of cynomolgus monkeys within 30 min of intramuscular injection of ketamine hydrochloride (Ketalar; Yuhan Co., Seoul, Korea) at a dose of 10 mg/ kg. The conditions, mentioned above, allowed animals to be handled without difficulty, and they appeared calm during the bleeding procedure. This study was reviewed and assessed by the Institutional Animal Care and Use Committee (IACUC) of KIT (Certification acquisition of Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) International in 1998).
Clinical Observations, body weight and food consumption
Animals were monitored once a day during the pretreatment period. Animals were monitored before and after dosing during the treatment period. If there were clinical signs including mortality, morbidity, general appearance and behavior changes, those were recorded with date, time of finding and duration. Body weights were recorded during the pre-treatment and treatment period of Day 1, Day 4, Day 7 and Day 14.
Food consumption was also recorded in the pre-treatment and treatment period of Day 5 and Day 12.
Hematological and serum biochemical assays
Hematological examination was carried out at Day 0, Day 1, Day 4, Day 7 and Day 14 after starting administration. Serum biochemical examination was carried out at Day 7, and Day 14 after starting administration. Blood samples were collected from all animals (fasted) by venipuncture. The methods used in the haematological analysis are presented in Table 1 . Haematological examinations were carried out by collecting blood from the cephalic vein and then treating with EDTA-2K. The items of haematological and serum biochemical analyses are presented in Table 1 . Haematological items were measured automatically using a haematological autoanalyzer (ADVIA Hematology System Bayer, U.S.A). For serum biochemical examination, blood samples were collected from the cephalic vein, allowed to clot and centrifuged at 3,000 rpm for 10 min to separate serum. Clinical chemistry items are presented in Table 1 . Serum biochemical items were measured by an autoanalyzer (Shimadzu CL-7200, Shimadzu Co., Japan), and items such as calcium, chloride, sodium and potassium were assayed using an ion autoanalyzer (644, Ciba-corning, U.S.A.). Table 2 . Body weight after 2 week-repeated doses of a newly developed oral heparin derivative in cynomolgus monkeys. 120.5 ± 0.2 120.2 ± 0.2 120.4 ± 0.1 120.5 ± 0.2 Day 12 * Each value represents mean ± SD (n=3). There was no significant difference between the control and treatment groups. 
Statistical analysis
Data such as body weight, food consumption, platelet-related and serum biochemical parameters were analyzed for homogeneity of variance using Bartlett's test (Sokal and Rohlf, 1981) . Homogeneous data was analyzed using the Analysis of Variance and the significance of inter-group differences analyzed using Dunnett's t test (Dunnett, 1964) . Statistical analyses were performed by comparing the different dose groups with the vehicle control group using Path/Tox System (ver 4.4.4, Xybion Medical Systems Corporation, USA) and Statistical Analysis Systems (SAS/ STAT Version 8.1, Cary, NC, USA). The level of significance was set to 5% (p < 0.05). Hematological parameters are compared using the paired t-test. The descriptive results are presented as mean ± SD.
RESULTS AND DISCUSSIONS
The development of orally active heparin has been in high demand for the prevention of DVT and PE, for which heparin should be administered over several months. However, side-effects of heparin have been reported such as osteopenia and heparin-induced thro mbocy topenia (H IT) (Cines et al ., 20 07; Menajovsky., 2005) . Osteopenia is caused as a result of heparin binding to osteoblast (Shauhnessy et al., 1995) , which then releases factors that activate osteoclast, whereas HIT results from heparin binding to platelet factor 4 act to form an epitope to which the HIT antibody binds (Visentin et al., 1994; Greinacher et al., 1994) .
In the present study, we evaluated the effects of two-week repeated dose of a newly developed oral heparin derivative in cynomolgus monkeys. Neither Table 5 . Platelet-related parameters after single close of a newly developed oral heparin derivative. MPV PCT PDW% Platelet Day 0 9.40 ± 1.11 0.33 ± 0.06 64.00 ± 7.74 350.00 ± 39.20 Control 9.80 ± 1.04 0.36 ± 0.06 65.50 ± 6.45 366.00 ± 57.60 T1 8.90 ± 0.67 0.42 ± 0.11 60.40 ± 4.59 463.00 ± 88.90 T2 9.50 ± 1.79 0.33 ± 0.03 63.40 ± 9.62 346.00 ± 39.00 T3 Day 1 9.10 ± 0.86 0.33 ± 0.06 64.20 ± 3.97 356.00 ± 33.60 Control 9.40 ± 0.55 0.34 ± 0.02 63.10 ± 3.65 369.00 ± 23.50 T1 9.50 ± 1.10 0.41 ± 0.11 67.10 ± 6.93 425.00 ± 87.50 T2 9.40 ± 1.82 0.31 ± 0.03 67.00 ± 8.83 336.00 ± 31.20 T3 Day 4 8.50 ± 0.36 0.31 ± 0.05 56.50 ± 1.52 359.00 ± 51.50 Control 9.50 ± 0.75 0.35 ± 0.03 62.70 ± 3.65 374.00 ± 34.60 T1 9.00 ± 0.46 0.42 ± 0.10 62.00 ± 4.30 464.00 ± 88.50 T2 9.20 ± 1.31 0.29 ± 0.01 67.50 ± 6.93 319.00 ± 38.50 T3 Day 7
8.80 ± 0.70 0.34 ± 0.07 59.70 ± 4.45 381.00 ± 66.70 Control 9.40 ± 0.35 0.36 ± 0.02 61.90 ± 2.75 384.00 ± 21.70 T1 9.00 ± 0.36 0.42 ± 0.09 60.70 ± 4.65 467.00 ± 82.80 T2 9.20 ± 1.37 0.31 ± 0.00 64.20 ± 8.64 340.00 ± 48.00 T3 Day 14 9.00 ± 0.81 0.35 ± 0.07 62.30 ± 9.65 386.00 ± 44.50 Control 9.20 ± 0.35 0.35 ± 0.03 63.10 ± 3.14 382.00 ± 34.50 T1 9.00 ± 0.72 0.41 ± 0.09 61.80 ± 2.87 449.00 ± 60.50 T2 9.40 ± 1.13 0.35 ± 0.06 67.10 ± 7.41 377.00 ± 33.90 T3 Each value represents as mean value (n= 3). PDW% (Platelet distribution width), PCT (Plateletcrit), MPV (Mean platelet volume). Vol. 32 No. 4 clinical signs nor food consumption were affected by treatment with the test article (Table 3) . Group mean body weight data are presented in Table 2 . Body weights were not affected by any of the test article. The hematological and serum biochemical items measured methods are summarized in Table 1. Table 4 shows the values for hemoglobin (Hb), hematocrit (HCT), reticulocytes, red blood cells (RBC) count, white blood cell (WBC) count, platelet count, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH) and mean corpuscular hemoglobin concentration (MCHC), and percent WBC for differential counts. Hematological parameters were not affected by the test article. Minor changes in WBC number at Day 1 and Day 4 were considered incidental and within the range of normal variability for the parameter (Matsuzawa et al., 1993; Kim et al., 2004) , or were related to study procedures (e.g., blood sampling and animal handling). As shown in Table 5 , platelet-related parameters were also not affected by the test article. Table 6 is a list of serum concentrations of aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphate(ALP), blood urea nitrogen (BUN), creatinine (CREA), glucose (GLU), total cholesterol (T-CHO), albumin/globulin (A/G), total protein (TP), albumin (ALB), creatine phosphokinase (CPK), triglyceride (TG), total bilirubin (T-BIL), inorganic phosphate (IP), calcium (Ca), chloride (Cl), sodium(Na) and potassium (K). Serum chemistry parameters were not affected by the test article (Table  7) . A decrease in serum biochemical parameter of AST level at Day 7 was considered incidental and within the range of normal variability for the parameter (Matsuzawa et al., 1993; Kim et al., 2004) . The present finding that the two-week repeated dose of the test article did not affect any effects in hematological and serum biochemical parameters was consistent with that found in the previous study, in which a single dose of the test article did not show any change in body weights, hematological and serum biochemical parameters at a dose of 500 mg/kg (Kim et al., 2007) .
In conclusion, the oral anticoagulant drug, a 179.00 ± 13.60 170.00 ± 42.30 156.00 ± 24.70 181.00 ± 45.00 PL (mg/dl) 0.14 ± 0.00 0.16 ± 0.02 0.18 ± 0.04 0.20 ± 0.02 T-BIL (mg/dl) 150.00 ± 1.50 149.00 ± 1.20 149.00 ± 1.20 149.00 ± 0.60 Na (mmol/l) 4.61 ± 0.34 4.22 ± 0.16 4.40 ± 0.03 4.52 ± 0.26 K (mmol/l) 113.00 ± 2.10 111.00 ± 1.50 112.00 ± 1.20 110.00 ± 2.60 Cl (mmol/l) Each value represents as mean value (n= 3). * Significant differences from control group (p<0.05). AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; BUN, blood urea nitrogen; CREA, creatinine; GLU, glucose; T-CHO, total cholesterol; A/G, albumin/globulin; TP, total protein; ALB, albumin; CPK, creatine phosphokinase; TG, triglyceride; IP, inorganic phosphate; PL, Phospolidpid; T-BIL, total bilirubin. newly developed oral heparin derivative, did not cause any changes in body weight, food consumption, hematological parameters (such as WBC, RBC, hemoglobin, hematocrit, hemoglobin and platelet counts, etc.) and serum biochemical parameters (AST, ALT, BUN, etc.). The present study will be valuable in the proper interpretation for non-clinical study using cynomolgus monkeys in the development of new drug any of heparin derivative.
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